Diagnosing the decline in pharmaceutical R&D efficiency
The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (RD). Yet the number of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining RD efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For over fifty years, the pharmaceutical industry has seen the cost of developing drugs increase exponentially from tens of millions in the 1950s to billions of dollars today, even when the data is adjusted for inflation [1].”
From Drug design on quantum computers (2024) · doi:10.1038/s41567-024-02411-5 · cites this paper as [1]
Citations
Cites
Collective dynamics of ‘small-world’ networks
Watts, D. J., & Strogatz, S. H. (1998) · Nature · doi:10.1038/30918 · Cited by 43,060
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“It is hard to look at the genesis of drugs like crizotini”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“First, estimates of the number of potential drug target”
BackgroundExplaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
Nucleotide sequence of bacteriophage G4 DNA
Godson, G. N., Barrell, B. G., Staden, R., & Fiddes, J. C. (1978) · Nature · doi:10.1038/276236a0 · Cited by 2,099
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Nucleotide sequence of bacteriophage φX174 DNA
Sanger, F., Air, G. M., Barrell, B. G., Brown, N. L., Coulson, A. R., Fiddes, J. C., Hutchison, C. A., Slocombe, P. M., & Smith, M. (1977) · Nature · doi:10.1038/265687a0 · Cited by 1,615 · cited 1×
“DNA sequencing has become over a billion times faster since the first genome sequence was determined in the 1970”
BackgroundImpact of high-throughput screening in biomedical research
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207 · cited 1×
“However, in parallel — as many have discussed — R&D efficiency, measured simply in terms of the number of new drugs brought to market by the global biotechnology and pharmaceutical industries per billion US dollars of R&D spending, has declined fairly steadil”
BackgroundRoth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.295 · Cited by 845
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
Multicomponent therapeutics for networked systems
Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769
Medical and Ethical Consequences of the Human Genome Project
Collins, F. S. (1991) · The Journal of Clinical Ethics · doi:10.1086/jce199102411 · Cited by 666
STREPTOMYCIN treatment of pulmonary tuberculosis.
D’Esopo, N. D., & Allison, S. T. (1947) · PubMed · Cited by 606
Medical and Societal Consequences of the Human Genome Project
Collins, F. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907013410106 · Cited by 578 · cited 1×
“: “Since the 1970s, nearly all avenues of biomedical research have led to the gene”
BackgroundProbing the links between in vitro potency, ADMET and physicochemical parameters
Gleeson, M. P., Hersey, A., Montanari, D., & Overington, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3367 · Cited by 503
Can we rationally design promiscuous drugs?
HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469
Healy, D. (1998) · DigitalGeorgetown (Georgetown University Library) · Cited by 467
The role of the medicinal chemist in drug discovery — then and now
Lombardino, J. G., & Lowe, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1523 · Cited by 452
Next-generation sequencing for cancer diagnostics: a practical perspective.
Meldrum, C. J., Doyle, M., & Tothill, R. W. (2011) · Europe PMC (PubMed Central) · Cited by 443
The druggable genome: an update
Russ, A. P., & Lampel, S. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03666-4 · Cited by 424 · cited 1×
“First, estimates of the number of potential drug target”
BackgroundScience Business: The Promise, the Reality and the Future of Biotech
Li, W. (2007) · Journal of Commercial Biotechnology · doi:10.1057/palgrave.jcb.3050059 · Cited by 409
Science Business: The Promise, the Reality and the Future of Biotech
Li, W. (1969) · Journal of Commercial Biotechnology · doi:10.5912/jcb219 · Cited by 340
Rise and fall of modern medicine
Le Fanu, J. (1999) · The Lancet · doi:10.1016/s0140-6736(05)75559-8 · Cited by 296
Denome, S. A., Elf, P. K., Henderson, T. A., Nelson, D. E., & Young, K. D. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.13.3981-3993.1999 · Cited by 288 · cited 1×
“Indeed, drug-like small molecules tend to bind promiscuously, and this sometimes turns out to have an important role in their efficac”
BackgroundA New Look at the Returns and Risks to Pharmaceutical R&D
Grabowski, H., & Vernon, J. (1990) · Management Science · doi:10.1287/mnsc.36.7.804 · Cited by 286
The Future of High-Throughput Screening
Mayr, L. M., & Fuerst, P. (2008) · SLAS Discovery · doi:10.1177/1087057108319644 · Cited by 276 · cited 1×
“High-throughput screening (HTS) has resulted in a tenfold reduction in the cost of testing compound libraries against protein targets since the mid-1990”
BackgroundHorrobin, D. F. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1012 · Cited by 248
SEQUENCES, SEQUENCES, AND SEQUENCES
Sanger, F. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.000245 · Cited by 246 · cited 1×
“DNA sequencing has become over a billion times faster since the first genome sequence was determined in the 1970”
BackgroundO'Shaughnessy, J., Schwartzberg, L. S., Danso, M. A., Rugo, H. S., Miller, K., Yardley, D. A., Carlson, R. W., Finn, R. S., Charpentier, E., Freese, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.1007 · Cited by 245
Rebuilding the R&D engine in big pharma.
Garnier, J.-P. (2008) · PubMed · Cited by 228
Combinatorial compound libraries for drug discovery: an ongoing challenge
Mario Geysen, H., Schoenen, F., Wagner, D., & Wagner, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1035 · Cited by 224
Lichtenberg, F. R. (2005) · International Journal of Health Care Finance and Economics · doi:10.1007/s10754-005-6601-7 · Cited by 200
Streptomycin in the treatment of pulmonary tuberculosis
Weitzman, D., de Wend Cayley, F. E., & Wingfield, A. L. (1950) · British Journal of Tuberculosis and Diseases of the Chest · doi:10.1016/s0366-0869(50)80004-7 · Cited by 189
Pharmaceutical Industry Profile
(2005) · Good Design Practices for GMP Pharmaceutical Facilities · doi:10.1201/9780849398537-6 · Cited by 179
Innovation in the pharmaceutical industry
Horrobin, D. F. (2000) · Journal of the Royal Society of Medicine · doi:10.1177/014107680009300702 · Cited by 173
The major role of clinicians in the discovery of off-label drug therapies
DeMonaco, H. J., Ali, A., & von Hippel, E. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.3.323 · Cited by 142 · cited 1×
“Even recently, it appears that many — perhaps most — new therapeutic uses of drugs have been discovered by motivated and observant clinicians working with patients in the real worl”
Research and Technical Change in the Pharmaceutical Industry
Comanor, W. S. (1965) · The Review of Economics and Statistics · doi:10.2307/1924065 · Cited by 141
Grabowski, H. G., Vernon, J. M., & Thomas, L. G. (1978) · The Journal of Law and Economics · doi:10.1086/466914 · Cited by 135
Research Expenditures and the Discovery of New Drugs
Jensen, E. J. (1987) · Journal of Industrial Economics · doi:10.2307/2098598 · Cited by 132
Obliquity: Why Our Goals Are Best Achieved Indirectly
Kay, J. (2010) · Medical Entomology and Zoology · Cited by 119
High-throughput crystallography for structural genomics☆
Joachimiak, A. (2009) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2009.08.002 · Cited by 119 · cited 1×
“It now takes at least three orders of magnitude fewer man-hours to calculate three-dimensional protein structure via X-ray crystallography than it did 50 years ag”
BackgroundPARP inhibitors stumble in breast cancer
Guha, M. (2011) · Nature Biotechnology · doi:10.1038/nbt0511-373 · Cited by 110
Research and Development Costs and Returns: The U.S. Pharmaceutical Industry
Baily, M. N. (1972) · Journal of Political Economy · doi:10.1086/259862 · Cited by 95
Pharmaceutical R&D: the road to positive returns
David, E., Tramontin, T., & Zemmel, R. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2948 · Cited by 94 · cited 1×
“However, readers of much of what has been written about R&D productivity in the drug industry might be left with the impression that Eroom's Law can simply be reversed by strategies such as greater management attention to factors such as project costs and speed of implementatio”
BackgroundCombinatorial chemistry in drug discovery
Hogan, J. C. (1997) · Nature Biotechnology · doi:10.1038/nbt0497-328 · Cited by 84 · cited 1×
“For example, combinatorial chemistry increased the number of drug-like molecules that could be synthesized per chemist per year by perhaps 800-fold during the 1980s and 1990”
BackgroundRealism in drug discovery—could Cassandra be right?
Horrobin, D. F. (2001) · Nature Biotechnology · doi:10.1038/nbt1201-1099 · Cited by 79
The slowing of treatment discovery, 1965–1995
Wurtman, R. J., & Bettiker, R. L. (1995) · Nature Medicine · doi:10.1038/nm1195-1122 · Cited by 73 · cited 1×
“In our view, the 'low-hanging fruit' explanation is sometimes tautological as 'technically easy' tends to be equated with 'already discovered”
RESEARCH AND DEVELOPMENT IN THE PHARMACEUTICAL INDUSTRY.
Smith, A. B. (1965) · PubMed · Cited by 71
Ainsworth, C. (2011) · Nature Medicine · doi:10.1038/nm1011-1166 · Cited by 55
The case for entrepreneurship in R&D in the pharmaceutical industry
Douglas, F. L., Narayanan, V. K., Mitchell, L., & Litan, R. E. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3230 · Cited by 48 · cited 1×
“, or by somehow making scientists more 'entrepreneurial”
BackgroundDrug innovation—what's slowing it down?
Steward, F., & Wibberley, G. (1980) · Nature · doi:10.1038/284118a0 · Cited by 44 · cited 1×
“The 'cautious regulator' problem was an obvious dra”
BackgroundAn end to the search for new drugs?
Weatherall, M. (1982) · Nature · doi:10.1038/296387a0 · Cited by 44 · cited 1×
“Progressive lowering of the risk tolerance of drug regulatory agencies obviously raises the bar for the introduction of new drugs, and could substantially increase the associated costs of R&”
BackgroundA closer look at the returns and risks of pharmaceutical R&D
Joglekar, P. N., & Paterson, M. L. (1986) · Journal of Health Economics · doi:10.1016/0167-6296(86)90003-2 · Cited by 39
Why has R&D productivity declined in the pharmaceutical industry?
Ruffolo, R. R., Jr. (2006) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.1.2.99 · Cited by 37 · cited 1×
“, arguing that bottom-up science has been a disappointing distraction; an article by Ruffol”
BackgroundFuture pathways for combinatorial chemistry
Brown, D. (1997) · Molecular Diversity · doi:10.1007/bf01715637 · Cited by 37
Grove, A. S. (2011) · Science · doi:10.1126/science.1212118 · Cited by 29
Historical Overview of Chemical Library Design
Dolle, R. E. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-931-4_1 · Cited by 29
Persson, C. G. A., Erjefalt, J. S., Uller, L., Andersson, M., & Greiff, L. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01839-3 · Cited by 23
Tollman, P., Morieux, Y., Murphy, J. K., & Schulze, U. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3555 · Cited by 21
Unlocking the Value in Big Pharma
Agarwal, S. D., Desai, S. R., Holcomb, M. M., & Oberoi, A. (2001) · The McKinsey Quarterly · Cited by 19
What went right: Why is HIV a treatable infection?
Richard, J., & Wurtman, M. D. (1997) · Nature Medicine · doi:10.1038/nm0797-714 · Cited by 19
Probabilities of success for antibody therapeutics
Reichert, J. M. (2009) · mAbs · doi:10.4161/mabs.1.4.9031 · Cited by 15 · cited 1×
“The high rates of success in clinical trials of monoclonal antibodies (and related fusion proteins) is perhaps more notabl”
BackgroundPost-genome integrative biology: so that’s what they call clinical science
Rees, J. (2001) · Clinical Medicine · doi:10.7861/clinmedicine.1-5-393 · Cited by 15
Mission possible: managing innovation in drug discovery
Zhong, X., & Moseley, G. B. (2007) · Nature Biotechnology · doi:10.1038/nbt0807-945 · Cited by 13 · cited 1×
“, or by somehow making scientists more 'entrepreneurial”
BackgroundBook Review: The Psychopharmacologists, Volume 3
Keks, N. A. (2002) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2002.t01-9-01055.x · Cited by 13
Development Cost: Determinants and Overruns
Schnee, J. E. (1972) · The Journal of Business · doi:10.1086/295463 · Cited by 12
Protein Architecture: Designing from the Ground Up
Brunt, J. V. (1986) · Nature Biotechnology · doi:10.1038/nbt0486-277 · Cited by 10
(2000) · Nature Biotechnology · doi:10.1038/80095 · Cited by 9
R&D strategy in the U.S. pharmaceutical industry
Schnee, J. E. (1979) · Research Policy · doi:10.1016/0048-7333(79)90003-9 · Cited by 8 · cited 1×
“There is another related potential cause of Eroom's Law that has frequently been put forward, termed the 'low-hanging fruit' problem, which results from the progressive exploitation of drug targets that are more technically tractabl”
BackgroundRethinking Clinical Trials: Biology's Mysteries
Borhani, D. W., & Butts, J. (2011) · Science · doi:10.1126/science.334.6061.1346-c · Cited by 4
(1980) · Nature · doi:10.1038/283609a0 · Cited by 3
Changes in the characteristics of approved New Drug Applications for antihypertensives
MacNeil, J. S. H. (2007) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 1
Lin, H.-L. S. (2007) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 1
Leading Hedgehog inhibitor submitted for approval as skin cancer drug
(2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3594 · Cited by 1
The art and practice of structure-based drug design: A molecular modeling perspective
(1996) · doi:10.1002/(sici)1098-1128(199601)16:1<3::aid-med1>3.0.co;2-6
Research works printed but not linked: 6
- Ruffolo, R. R. Engineering success: Wyeth redefines its research & development organisation. Drug Discovery World website [online] , (2005).
- Young, M. P. Prediction v Attrition. Drug Discovery World website [online] , (2008).
- Healy, D. The Psychopharmacologists: Volume 2 93–118 (Hodder Arnold, London, 1999).
- Healy, D. The Psychopharmacologists: Volume 2 259–264 (Hodder Arnold, London, 1999).
- Mathieu, M. P. (ed.) Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2010/2011 163–261 (Barnett International, Needham, Massachusetts, 2010).
- Munos, B. How to avert biopharma's R&D crisis. In Vivo 29, 2011800050 (2011).
Cited by
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Discovery and resupply of pharmacologically active plant-derived natural products: A review
Atanasov, A. G., Waltenberger, B., Pferschy-Wenzig, E.-M., Linder, T., Wawrosch, C., Uhrin, P., Temml, V., Wang, L., Schwaiger, S., Heiss, E. H., et al. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.08.001 · Cited by 2,904
“The obtained results, however, did not meet the expectations as evident in a declining number of new drugs reaching the market (David et al., 2015; Kingston, 2011; Scannell et al., 2012).”
BackgroundResultInfluentialLessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
“11 (5) Evidence from previous phase not robust enough”
BackgroundNetwork pharmacology: curing causal mechanisms instead of treating symptoms
Nogales, C., Mamdouh, Z. M., List, M., Kiel, C., Casas, A. I., & Schmidt, H. H. H. W. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.11.004 · Cited by 1,201
Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design
Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071916 · Cited by 1,061
“The global outbreak of COVID-19 has caused significant disruptions to various operations worldwide, including ongoing clinical trials (Chavda, et al, 2023).”
Background
Metadata
- Authors
- Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B.
- Corresponding author
- Scannell, Jack W.
- ORCID
- Scannell, Jack W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-03
- Volume
- 11
- Issue
- 3
- Pages
- 191-200
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2028279608
- Cited by
- 1,981
- References
- 85
- Citations by year
- 2026: 135 · 2025: 123 · 2024: 144 · 2023: 126 · 2022: 141 · 2021: 173 · 2020: 178 · 2019: 144 · 2018: 138 · 2017: 133 · 2016: 155 · 2015: 136 · 2014: 108 · 2013: 103 · 2012: 41
- FWCI
- 47.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- new drug approvals, drug approval rates, drug development costs, regulatory policy, drug regulation, basic research
- MeSH terms
- Animals, Drug Industry, Pharmaceutical Preparations, Humans, Research, Drug Delivery Systems, Efficiency, Organizational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.